AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21527516 — intervention group
Group type: EXPERIMENTAL
Intervention: HLA-haploidentical related donor bone marrow (Haplo-marrow) transplantation
Number of subjects: 100
Study 19626381 — intervention group
Group type: EXPERIMENTAL
Intervention: Respiratory physiotherapy during PACU stay
Number of subjects: 60
Study 19626381 — intervention group
Group type: COMPARATOR
Intervention: Routine treatment (Control)
Number of subjects: 60
Study 17357049 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal administration of citrate/phosphate (CP) buffer
Number of subjects: 0
Study 17357049 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study 15529558 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-energy transvenous internal cardioversion (ICV)
Number of subjects: 52
Study 15529558 — intervention group
Group type: COMPARATOR
Intervention: Transthoracic cardioversion (TT)
Number of subjects: 52
Study 11176554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient programs that shortened their average length of stay
Number of subjects: 6397
Study 11176554 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient programs that converted to residential treatment
Number of subjects: 6397
Study 11176554 — intervention group
Group type: EXPERIMENTAL
Intervention: Residential treatment programs established before the period of change
Number of subjects: 6397
Study 11176554 — intervention group
Group type: COMPARATOR
Intervention: Inpatient PTSD programs that did not experience program change
Number of subjects: 6397
Study 9141935 — intervention group
Group type: EXPERIMENTAL
Intervention: LA‐IVRA (90 mg of lysine acetylsalicylate mixed with prilocaine 0.5%)
Number of subjects: 60
Study 9141935 — intervention group
Group type: EXPERIMENTAL
Intervention: LA‐IV (1 mL of 0.9% NaCl mixed with prilocaine and 90 mg of LA administered IV)
Number of subjects: 60
Study 9141935 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1 mL of 0.9% NaCl administered with prilocaine for IVRA and IV)
Number of subjects: 60
Study 7895787 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with left FEF lesions
Number of subjects: 15
Study 2880687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen (single dose) with 100 mg fenoldopam
Number of subjects: 19
Study 2880687 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen (chronic dosing for 7 days) with 100 mg fenoldopam
Number of subjects: 19
Study 2880687 — intervention group
Group type: COMPARATOR
Intervention: 100 mg fenoldopam alone
Number of subjects: 19
Study 2880687 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg fenoldopam with 1000 mg acetaminophen
Number of subjects: 19
Study 29605408 — intervention group
Group type: EXPERIMENTAL
Intervention: COC‐ICSI
Number of subjects: 60
Study 29605408 — intervention group
Group type: COMPARATOR
Intervention: C‐ICSI
Number of subjects: 60
Study 26980323 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-based mindfulness intervention (FBMI)
Number of subjects: 120
Study 26980323 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 120
Study 25676256 — intervention group
Group type: EXPERIMENTAL
Intervention: Scarcity conditions
Number of subjects: 0
Study 22147680 — intervention group
Group type: EXPERIMENTAL
Intervention: 6RM training protocol (3 sets of 6RM, twice per week for 8 weeks)
Number of subjects: 62
Study 22147680 — intervention group
Group type: EXPERIMENTAL
Intervention: 12RM training protocol (3 sets of 12RM, twice per week for 8 weeks)
Number of subjects: 62
Study 22147680 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned, but implied as the comparison between 6RM and 12RM)
Number of subjects: 62
Study 22147680 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (6RM and 12RM)
Number of subjects: 62
Study 19637942 — intervention group
Group type: COMPARATOR
Intervention: Long-acting beta(2)-agonists
Number of subjects: 31020
Study 19637942 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium
Number of subjects: 31020
Study 19637942 — intervention group
Group type: COMPARATOR
Intervention: Inhaled corticosteroids
Number of subjects: 31020
Study 19637942 — intervention group
Group type: COMPARATOR
Intervention: Combination inhaled corticosteroid-long-acting beta(2)-agonist therapy
Number of subjects: 31020
Study 19637942 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy vs Tiotropium
Number of subjects: 31020
Study 17192290 — intervention group
Group type: COMPARATOR
Intervention: Endothelial-dependent vasodilation in obese women
Number of subjects: 60
Study 17192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Endothelial-dependent vasodilation in lean women
Number of subjects: 60
Study 17192290 — intervention group
Group type: COMPARATOR
Intervention: Endothelial-independent vasodilation
Number of subjects: 60
Study 17192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of time of sampling on endothelial-independent function
Number of subjects: 60
Study 17192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Impact of obesity on endothelial-dependent microvascular function
Number of subjects: 60
Study 17192290 — intervention group
Group type: COMPARATOR
Intervention: PAI-1/PAI-2 ratio in 1st trimester
Number of subjects: 60
Study 17192290 — intervention group
Group type: EXPERIMENTAL
Intervention: Contributors to 1st trimester PAI-1/PAI-2 ratio
Number of subjects: 60
Study 14700518 — intervention group
Group type: EXPERIMENTAL
Intervention: valsartan 80 mg
Number of subjects: 120
Study 14700518 — intervention group
Group type: COMPARATOR
Intervention: atenolol 50 mg
Number of subjects: 120
Study 12469919 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate 10 mg daily
Number of subjects: 41
Study 12469919 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9829840 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin + 5-FU (Regimen A)
Number of subjects: 33
Study 9829840 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin + 5-FU + recombinant interleukin 2 (Regimen B)
Number of subjects: 33
Study 8273807 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg P.O. t.i.d. for 3 consecutive days
Number of subjects: 20
Study 2510260 — intervention group
Group type: EXPERIMENTAL
Intervention: Rioprostil 600 micrograms once-daily orally
Number of subjects: 207
Study 2510260 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg once-daily orally
Number of subjects: 207
Study 168493 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic response to exercise (Group A)
Number of subjects: 89
Study 168493 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic response to exercise (Group B)
Number of subjects: 89
Study 168493 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrocardiographic response to exercise (Group C)
Number of subjects: 89
Study 31905307 — intervention group
Group type: EXPERIMENTAL
Intervention: M‐ACT (multimodal acceptance and commitment therapy)
Number of subjects: 35
Study 31740595 — intervention group
Group type: EXPERIMENTAL
Intervention: Stakeholder Engagement (SE) intervention
Number of subjects: 107
Study 31740595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not participating in SE)
Number of subjects: 107
Study 30187159 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine (n=15)
Number of subjects: 48
Study 30187159 — intervention group
Group type: EXPERIMENTAL
Intervention: Prucalopride (n=14)
Number of subjects: 48
Study 30187159 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=13)
Number of subjects: 48
Study 27697605 — intervention group
Group type: EXPERIMENTAL
Intervention: i-gel supraglottic airway device
Number of subjects: 9070
Study 27697605 — intervention group
Group type: COMPARATOR
Intervention: tracheal intubation
Number of subjects: 9070
Study 24762369 — intervention group
Group type: EXPERIMENTAL
Intervention: Transactional Model-based Teaching program
Number of subjects: 200
Study 24762369 — intervention group
Group type: COMPARATOR
Intervention: Ordinary Education Curriculum-based Teaching program
Number of subjects: 200
Study 21823769 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention (CDI)
Number of subjects: 226
Study 21823769 — intervention group
Group type: COMPARATOR
Intervention: Assessment-only control group
Number of subjects: 226
Study 21823769 — intervention group
Group type: COMPARATOR
Intervention: Delayed-assessment control group
Number of subjects: 226
Study 20562617 — intervention group
Group type: EXPERIMENTAL
Intervention: CVC self-care training (n = 42)
Number of subjects: 82
Study 20562617 — intervention group
Group type: COMPARATOR
Intervention: Standard CVC procedure provided by nurses (n = 40)
Number of subjects: 82
Study 17702132 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 0
Study 17702132 — intervention group
Group type: COMPARATOR
Intervention: Post-surgical adjuvant chemotherapy
Number of subjects: 0
Study 17702132 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy or chemotherapy with subsequent surgery
Number of subjects: 0
Study 15642569 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 75 mg
Number of subjects: 624
Study 15642569 — intervention group
Group type: EXPERIMENTAL
Intervention: Azimilide 125 mg
Number of subjects: 624
Study 15642569 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 624
Study 11842294 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 39
Study 11842294 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 9495402 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 1%/sufentanil
Number of subjects: 80
Study 9495402 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane/sufentanil
Number of subjects: 80
Study 9495402 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane/sufentanil
Number of subjects: 80
Study 9495402 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane/sufentanil (standard anesthesia)
Number of subjects: 80
Study 7644046 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 151
Study 7644046 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 151
Study 2757939 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA sunbeds (3 times weekly for 4 weeks)
Number of subjects: 31
Study 2757939 — intervention group
Group type: COMPARATOR
Intervention: Visible light sunbeds (3 times weekly for 4 weeks)
Number of subjects: 31
Study 2757939 — intervention group
Group type: EXPERIMENTAL
Intervention: UVA sunbeds and Visible light sunbeds
Number of subjects: 31
Study 359779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral codeine
Number of subjects: 0
Study 359779 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular codeine
Number of subjects: 0
Study 359779 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxycodone
Number of subjects: 0
Study 359779 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular oxycodone
Number of subjects: 0
Study 31854193 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-minute mindful breathing
Number of subjects: 40
Study 31854193 — intervention group
Group type: COMPARATOR
Intervention: 20-minute supportive listening
Number of subjects: 40
Study 31034184 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (up to 1.8 mg per day)
Number of subjects: 135
Study 31034184 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135
Study 31034184 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 135
Study 28192782 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG biofeedback (14 sessions over 8 weeks)
Number of subjects: 36
Study 28192782 — intervention group
Group type: COMPARATOR
Intervention: Control (usual care alone)
Number of subjects: 36
Study 25376453 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone
Number of subjects: 142
Study 25376453 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (≥4 cycles)
Number of subjects: 142
Study 25376453 — intervention group
Group type: EXPERIMENTAL
Intervention: Progesterone (≥4 years follow-up)
Number of subjects: 142
Study 25376453 — intervention group
Group type: COMPARATOR
Intervention: Any fertility drug
Number of subjects: 142
Study 25376453 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophins
Number of subjects: 142
Study 25376453 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene citrate
Number of subjects: 142
Study 25376453 — intervention group
Group type: COMPARATOR
Intervention: Human chorionic gonadotrophins
Number of subjects: 142
Study 25376453 — intervention group
Group type: COMPARATOR
Intervention: Gonadotrophin-releasing hormone analogues
Number of subjects: 142
Study 23360509 — intervention group
Group type: EXPERIMENTAL
Intervention: Global radial strain (εR)
Number of subjects: 215
Study 23360509 — intervention group
Group type: EXPERIMENTAL
Intervention: Global longitudinal strain (εL)
Number of subjects: 215
Study 23360509 — intervention group
Group type: EXPERIMENTAL
Intervention: Global circumferential strain (εC)
Number of subjects: 215
Study 23360509 — intervention group
Group type: EXPERIMENTAL
Intervention: Interaction of εL and εC
Number of subjects: 215
Study 21760722 — intervention group
Group type: EXPERIMENTAL
Intervention: Breezhaler
Number of subjects: 82
Study 21760722 — intervention group
Group type: EXPERIMENTAL
Intervention: HandiHaler
Number of subjects: 82
Study 19801236 — intervention group
Group type: EXPERIMENTAL
Intervention: BioAggregate
Number of subjects: 56
Study 19801236 — intervention group
Group type: EXPERIMENTAL
Intervention: MTA
Number of subjects: 56
Study 19801236 — intervention group
Group type: COMPARATOR
Intervention: Control (empty root canals)
Number of subjects: 56
Study 17241835 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (109 women who removed their IUD for planning pregnancy)
Number of subjects: 205
Study 17241835 — intervention group
Group type: COMPARATOR
Intervention: Group B (96 women who became pregnant or planned pregnancy after complicated IUD use)
Number of subjects: 205
Study 17241835 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A
Number of subjects: 205
Study 17241835 — intervention group
Group type: COMPARATOR
Intervention: Group B
Number of subjects: 205
Study 17241835 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A and Group B
Number of subjects: 205
Study 15133773 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief counseling program directed at couples with cancer
Number of subjects: 0
Study 15133773 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list group (control)
Number of subjects: 0
Study 11511297 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultraviolet irradiation (2 minimal erythema doses)
Number of subjects: 0
Study 11511297 — intervention group
Group type: COMPARATOR
Intervention: Clobetasol (glucocorticoid)
Number of subjects: 0
Study 11511297 — intervention group
Group type: COMPARATOR
Intervention: All-trans retinoic acid
Number of subjects: 0
Study 10205771 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetaminophen (APAP) 12.5 mg/kg
Number of subjects: 178
Study 10205771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 5 mg/kg
Number of subjects: 178
Study 10205771 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (IBU) 10 mg/kg
Number of subjects: 178
Study 10205771 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 178
Study 7972977 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetracycline
Number of subjects: 40
Study 7972977 — intervention group
Group type: COMPARATOR
Intervention: Mechlorethamine
Number of subjects: 40
Study 2787232 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose, frequent-injection group (injection volumes of less than 10 cc at mean intervals of three days)
Number of subjects: 0
Study 2787232 — intervention group
Group type: COMPARATOR
Intervention: Large-dose weekly treatment group (injection volumes greater than 15 cc at weekly intervals)
Number of subjects: 0
Study 2787232 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-dose, frequent-injection group
Number of subjects: 0
Study 2787232 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 5090826 — intervention group
Group type: EXPERIMENTAL
Intervention: Betamethasone 17-valerate (5 mg) retention enema
Number of subjects: 0
Study 5090826 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone 21-phosphate (20 mg) retention enema
Number of subjects: 0
Study 31567351 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramelteon 8 mg
Number of subjects: 120
Study 31567351 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 29042415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet (goal: 10% weight loss, N = 118)
Number of subjects: 439
Study 29042415 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (225 min/wk moderate‐to‐vigorous activity, N = 117)
Number of subjects: 439
Study 29042415 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet + Exercise (N = 117)
Number of subjects: 439
Study 29042415 — intervention group
Group type: COMPARATOR
Intervention: Control (N = 87)
Number of subjects: 439
Study 29042415 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining ≥10% of baseline weight loss
Number of subjects: 439
Study 29042415 — intervention group
Group type: EXPERIMENTAL
Intervention: Maintaining any weight loss
Number of subjects: 439
Study 26140473 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (200mg/d for 12 weeks)
Number of subjects: 64
Study 26140473 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 23238444 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral injection of 2.5-3.75 U BTA combined with sodium hyaluronate (SH) to the medial rectus muscle.
Number of subjects: 47
Study 23238444 — intervention group
Group type: COMPARATOR
Intervention: Bilateral injection of 2.5-3.75 U BTA solution alone to the medial rectus muscle.
Number of subjects: 47
Study 22088133 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Lifestyle Programme (12 fortnightly family sessions)
Number of subjects: 200
Study 22088133 — intervention group
Group type: COMPARATOR
Intervention: Enhanced standard care
Number of subjects: 200
Study 22088133 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Eating Lifestyle Programme
Number of subjects: 200
Study 19732191 — intervention group
Group type: EXPERIMENTAL
Intervention: Atraumatic restorative treatment (ART) restorations with cavity size between 2 and 3 mm or volumes 10.0-19.9 mm(3)
Number of subjects: 804
Study 16997837 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg kg(‐1) rocuronium
Number of subjects: 25
Study 16997837 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 25
Study 15160663 — intervention group
Group type: EXPERIMENTAL
Intervention: Colforsin (0.25 to 0.5 microg x kg(‐1) x min(‐1) loading dosage increased every 60 minutes)
Number of subjects: 18
Study 15160663 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 18
Study 11301640 — intervention group
Group type: EXPERIMENTAL
Intervention: Rayon tape
Number of subjects: 0
Study 11301640 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrylate adhesive tapes
Number of subjects: 0
Study 11301640 — intervention group
Group type: EXPERIMENTAL
Intervention: All tapes
Number of subjects: 0
Study 11301640 — intervention group
Group type: EXPERIMENTAL
Intervention: Individuals with varying responses
Number of subjects: 0
Study 9051366 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose (50 to 300 mg t.i.d.)
Number of subjects: 0
Study 9051366 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 9051366 — intervention group
Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 0
Study 8298548 — intervention group
Group type: EXPERIMENTAL
Intervention: Asthma Symptom Checklist (ASC)
Number of subjects: 42
Study 8298548 — intervention group
Group type: EXPERIMENTAL
Intervention: Living with Asthma Questionnaire (LWAQ)
Number of subjects: 42
Study 3524065 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (50 mg t.i.d.)
Number of subjects: 32
Study 3524065 — intervention group
Group type: EXPERIMENTAL
Intervention: Acemethacin (60 mg t.i.d.)
Number of subjects: 32
Study 3524065 — intervention group
Group type: EXPERIMENTAL
Intervention: Proglumethacin (150 mg t.i.d.)
Number of subjects: 32
Study 29355982 — intervention group
Group type: EXPERIMENTAL
Intervention: iPad applications requiring specific motor skills, used for 30 minutes daily for 9 weeks
Number of subjects: 53
Study 29355982 — intervention group
Group type: COMPARATOR
Intervention: Control class (no specific intervention mentioned)
Number of subjects: 53
Study 26738646 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-hour recovery time after liver biopsy
Number of subjects: 128
Study 26738646 — intervention group
Group type: COMPARATOR
Intervention: 6-hour recovery time after liver biopsy
Number of subjects: 128
Study 25358225 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 4 mg
Number of subjects: 40
Study 25358225 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 4 mg with dexamethasone 8 mg
Number of subjects: 40
Study 22098167 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual distraction (AV) via a wall-mounted 32" television with wireless headphones
Number of subjects: 118
Study 22098167 — intervention group
Group type: COMPARATOR
Intervention: No AV distraction (Control)
Number of subjects: 118
Study 20008860 — intervention group
Group type: EXPERIMENTAL
Intervention: Desflurane at 1 MAC in oxygen 100%
Number of subjects: 44
Study 20008860 — intervention group
Group type: COMPARATOR
Intervention: Oxygen 100% (control group)
Number of subjects: 44
Study 18949663 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated testing
Number of subjects: 0
Study 18949663 — intervention group
Group type: EXPERIMENTAL
Intervention: Correct information
Number of subjects: 0
Study 18949663 — intervention group
Group type: EXPERIMENTAL
Intervention: Misleading information
Number of subjects: 0
Study 18949663 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed testing
Number of subjects: 0
Study 16026700 — intervention group
Group type: EXPERIMENTAL
Intervention: VersaBond bone cement
Number of subjects: 59
Study 16026700 — intervention group
Group type: COMPARATOR
Intervention: Palacos R bone cement
Number of subjects: 59
Study 12538197 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1 mg (Group I, n=64)
Number of subjects: 206